Kara L Holloway-Kew 1, Pamela Rufus-Membere 2, Kara B Anderson 2, Amelia Betson 2, James Gaston 2, Mark A Kotowicz 3, Adolfo Diez-Perez 4, Natalie K Hyde 2, Julie A Pasco 5 Bone. 2020 Apr;133:115241. doi: 10.1016/j.bone.2020.115241. Epub 2020 Jan […]
F Malgo 1, N A T Hamdy 1, T J Rabelink 2, H M Kroon 3, K M J A Claessen 4, A M Pereira 4, N R Biermasz 4, N M Appelman-Dijkstra 1 Eur
Kara L Holloway-Kew 1, Amelia Betson 2, Pamela G Rufus-Membere 2, James Gaston 2, Adolfo Diez-Perez 3, Mark A Kotowicz 4, Julie A Pasco 5 Bone. 2021 Jan;142:115685. doi: 10.1016/j.bone.2020.115685. Epub 2020 Oct
Unni Syversen 1 2, Mats Peder Mosti 1 3, Ida Maria Mynarek 1, Trude Seselie Jahr Vedal 1, Kristin Aasarød 1 4, Trude Basso 5, Janne E Reseland 6, Per Medbøe Thorsby 7, Bjorn O Asvold 2 8, Erik Fink Eriksen 6, Astrid Kamilla
Kara L Holloway-Kew 1, Amelia Betson 2, Pamela G Rufus-Membere 2, James Gaston 2, Adolfo Diez-Perez 3, Mark A Kotowicz 4, Julie A Pasco 5PMID: 33049369DOI: 10.1016/j.bone.2020.115685 Background: Individuals with type 2 diabetes (T2DM) are
Sundeep Khosla 1, Parinya Samakkarnthai 2 3, David G Monroe 2, Joshua N Farr 2PMID: 34518671PMCID: PMC8605611DOI: 10.1038/s41574-021-00555-5 Fracture risk is increased in patients with type 2 diabetes mellitus
Nicola Hepp 1, Lars Folkestad 2, Simone Møllebæk 3, Anja Lisbeth Frederiksen 4, Morten Duno 5, Niklas Rye Jørgensen 6, Anne Pernille Hermann 3, Jens-Erik Beck Jensen 7PMID: 35421614DOI: 10.1016/j.bone.2022.116420 Background: Hypophosphatasia (HPP) is an autosomal recessive
Diana Ovejero 1, Natalia Garcia-Giralt 2, Núria Martínez-Gil 3, Raquel Rabionet 3, Susanna Balcells 3, Daniel Grinberg 3, Luis Alberto Pérez-Jurado 4, Xavier Nogués 2, Iñigo Etxebarria-Forondad 5PMID: 35623613DOI: 10.1016/j.bone.2022.116450 High bone mass (HBM) disorders are a clinically
Eva M Wölfel 1, Imke A K Fiedler 2, Sofie Dragoun Kolibova 1, Johannes Krug 1, Mei-Chun Lin 1, Bashar Yazigi 1, Anna K Siebels 1, Herbert Mushumba 3, Birgit Wulff 3, Benjamin Ondruschka 3, Klaus Püschel 3, Claus C Glüer 4, Katharina Jähn-Rickert 5, Björn
Eva M Wölfel 1, Imke A K Fiedler 2, Sofie Dragoun Kolibova 1, Johannes Krug 1, Mei-Chun Lin 1, Bashar Yazigi 1, Anna K Siebels 1, Herbert Mushumba 3, Birgit Wulff 3, Benjamin Ondruschka 3, Klaus Püschel 3, Claus C Glüer 4, Katharina Jähn-Rickert 5, Björn
Indication For Use and Safety Information
The OsteoProbe is indicated for use as a measurement tool to measure bone tissue resistance to microindentation on the tibia in adults. The clinical significance of resistance to microindentation is unknown. The device is not intended to diagnose or treat any clinical condition.
Like with any percutaneous procedure, there is a small risk of infection. The sale, distribution, and use of the OsteoProbe are restricted to prescription use. Federal law (United States of America) restricts this device to use by, or on the order of, a physician.
This website uses cookies to enhance the user experience. By using this site you agree to our privacy policy
This website uses cookies to enhance the user experience. By using this site you agree to our privacy policy